FDA Grants Orphan Drug Designation to Eftilagimod Alfa for Soft Tissue Sarcoma

The FDA has granted orphan drug designation to eftilagimod alfa, an investigational immunotherapy, for the treatment of soft tissue sarcoma. The Phase II trial met its primary end point tumor of hyalinization/fibrosis across multiple sarcoma subtypes with the combination of eftilagimod alfa, radiotherapy, and pembrolizumab.